Cardiovascular Drugs Market Key Players-Business, Deal & Patent Strategies and Manufacturers and Recent Developments

Top Companies in the Cardiovascular Drugs Market

• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol Myers Squibb
• Daiichi Sankyo Company, Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Servier Laboratories
• Viatris Inc.

Cardiovascular Drugs Market Growth:

The global cardiovascular drugs market size is calculated at US$ 150.02 billion in 2024, grew to US$155.53 billion in 2025, and is projected to reach around US$ 213.36 billion by 2034. The market is expanding at a CAGR of 3.65% between 2025 and 2034.

What are the Major Cardiovascular Drugs Market Trends?

Growth in cardiovascular diseases: There is a growth in cardiovascular diseases, which is increasing the demand for the use of safe and effective cardiovascular drugs. This, in turn, is increasing their research and development, leading to their new innovations. At the same time, to support these innovations, acquisitions and investments are being made by the companies.

For instance,

• In September 2025, to bolster the cardiovascular pipeline, an acquisition of Tourmaline Bio for $1.4 billion was announced by Novartis. Additionally, pacibekitug, a drug for the treatment of atherosclerotic cardiovascular disease, developed by Tourmaline, is in advanced phase 2 clinical trials as per Novartis.
• In February 2025, to expand the prospects in cardiometabolic disease, deals are being planned by Novartis to acquire Anthos Therapeutics with $925 million up front. Moreover, this milestone achievement can be around $3.1 billion.

Cardiovascular Drugs Market Value Chain Analysis

R&D

To enhance the existing therapies and to discover and develop new drug candidates to treat and prevent cardiovascular diseases is the main focus of the R&D of cardiovascular drugs.

Key Players: Novartis AG, Bayer AG, AstraZeneca plc, Sanofi S.A., Bristol Myers Squibb, Merck & Co., Inc.

Formulation and Final Dosage Preparation

The formulation and final dosage preparation of cardiovascular drugs consists of the development of safe, effective, stable, and patient-friendly dosage forms such as tablets, capsules, patches, and injectables.

Key Players: Novartis AG, AstraZeneca plc, Daiichi Sankyo Company, Ltd., Pfizer Inc.

Patient Support and Services

The patient support and services of the cardiovascular diseases focus on providing medication education, counselling, and financial assistance programs.

Key Players: Novartis AG, Sanofi S.A., Lupin.

Latest Announcements by Industry Leaders

In June 2025, after the launch of Biscado (Bisoprolol), the spokesperson at Cadila Pharmaceuticals Limited stated that, in the cardiovascular epidemic, India is the epicentre, with elevated heart rate as the modifiable risk factor. Thus, with these growing diseases, a clinically proven solution for patients and physicians is provided by the launch of Biscado. 

What are the Recent Developments in the Cardiovascular Drugs Market?

• In September 2025, to enhance the development of VMX-C001, a collaboration between CSL and VarmX BV was announced. VMX-C001 will be used to restore blood coagulation in patients with severe bleeding due to Factor Xa direct oral anticoagulants or who are in urgent need of surgery.
• In March 2025, Mineralys Therapeutics, Inc. announced, lorundrostat, used to treat uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), showed positive topline data of safety and efficacy in the Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials. Therefore, due to their promising safety and tolerability profile, both trials were considered to be successful.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com